Patent SG-11201906509W-A (SG)
Title: Lipocalin muteins with binding affinity for lag-3
Inventor: ROTHE CHRISTINE
IPC: A61K38/00
Filed: 2018-01-18
Abstract: NO C (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 26 July 2018 (26.07.2018) WIP0 I PCT omit VIII °nolo olo 010IIII 1111101 ow (10) International Publication Number WO 2018/134274 Al (51) International Patent Classification: C07K 14/47 (2006.01) A61K 38/00 (2006.01) (21) International Application Number: PCT/EP2018/051139 (22) International Filing Date: 18 January 2018 (18.01.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 17151945.7 18 January 2017 (18.01.2017) EP (71) Applicant: PIERIS PHARMACEUTICALS GMBH [DE/DE]; Lise-Meitner-Strasse 30, 85354 Freising-Wei- henstephan (DE). (72) Inventors: ROTHE, Christine; Heinrich-Niko- laus-Strasse 26, 85221 Dachau (DE). OLWILL, Shane; Am Waldrand 23a, 84354 Freising (DE). ALLERS- DORFER, Andrea; Mozartstrasse 20A, 85283 Wolnzach (DE). EICHNER, Timo; Bismarkstrasse 22, 85354 Freis- ing (DE). BEL AIBA, Rachida Siham; Erhardtstrasse 15, 80469 Munich (DE). PAVLIDOU, Marina; Kathari- na-Geisler-Str. 15, 85356 Freising (DE). (74) Agent: SCHIWECK, Wolfram et al.; Schiweck Weinzierl Koch, European Patent Attorneys, Landsberger Strasse 98, 80339 Munich (DE). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) — with sequence listing part of description (Rule 5.2(a)) (54) Title: LIPOCALIN MUTEINS WITH BINDING AFFINITY FOR LAG-3 (57) : The present disclosure provides human tear lipocalin muteins that specifically bind to LAG-3, which can be used in pharmaceutical applications, for example, as anti-cancer agents and/or immune modulators for the treatment or prevention of human diseases such as cancer, infectious diseases, and autoimmune diseases. The present disclosure further shows the human lipocalin muteins can inhibit the binding of LAG-3 to MHC class II on cells overexpressing MHC class II. The present disclosure also concerns methods of making LAG-3 binding lipocalin muteins described herein as well as compositions comprising such lipocalin muteins. The present disclosure further relates to nucleic acid molecules encoding such lipocalin muteins and to methods for generation of such lipocalin muteins and nucleic acid molecules. In addition, the application discloses therapeutic and/or diagnostic uses of these lipocalin muteins as well as compositions comprising one or more of such lipocalin muteins.